Staging hepatic fibrosis: Comparison of gadoxetate disodium-enhanced and diffusion-weighted mr imaging - Preliminary observations

Radiology

Volumn 259, Issue 1, 2011, Pages 142-150

  Watanabe, Haruo ^a   Kanematsu, Masayuki ^a,b   Goshima, Satoshi ^a   Kondo, Hiroshi ^a   Onozuka, Minoru ^b   Moriyama, Noriyuki ^c   Bae, Kyongtae T ^d  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

^b KANAGAWA DENTAL COLLEGE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; ECHOVIST; GADOXETIC ACID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SCORING SYSTEM; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79953002508     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10100621     Document Type: Article

References (42)

1. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99(6):1160-1174. (Pubitemid 38917824)
2. Buti M, San Miguel R, Brosa M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005;42(5):639-645.
3. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002;36(5 suppl 1):S161-S172. (Pubitemid 35253477)
4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344(7):495-500. (Pubitemid 32164902)
5. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2(2):165-173. (Pubitemid 16125908)
6. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97(10):2614-2618.
7. Annet L, Peeters F, Abarca-Quinones J, Leclercq I, Moulin P, Van Beers BE. Assessment of diffusion-weighted MR imaging in liver fibrosis. J Magn Reson Imaging 2007;25(1):122-128. (Pubitemid 46098861)
8. Koinuma M, Ohashi I, Hanafusa K, Shibuya H. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 2005;22(1):80-85. (Pubitemid 40885132)
9. Lewin M, Poujol-Robert A, Boëlle PY, et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007;46(3):658-665. (Pubitemid 47436110)
10. Sandrasegaran K, Akisik FM, Lin C, et al. Value of diffusion-weighted MRI for assessing liver fibrosis and cirrhosis. AJR Am J Roentgenol 2009;193(6):1556-1560.
11. Hagiwara M, Rusinek H, Lee VS, et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging - initial experience. Radiology 2008;246(3):926-934.
12. Huwart L, Sempoux C, Salameh N, et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Ra diology 2007;245(2):458-466. (Pubitemid 47612527)
13. Rouvière O, Yin M, Dresner MA, et al. MR elastography of the liver: preliminary results. Radiology 2006;240(2):440-448. (Pubitemid 44098640)
14. Kim H, Taksali SE, Dufour S, et al. Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, twopoint dixon and three-point IDEAL. Magn Reson Med 2008;59(3):521-527. (Pubitemid 351348223)
15. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004;230(1):266-275. (Pubitemid 37549812)
16. Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200(1):59-67. (Pubitemid 26197732)
17. Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 1997;7(2):275-280. (Pubitemid 127538595)
18. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L. Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI. J Magn Reson Imaging 2009;29(6):1323-1331.
19. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 2009;193(4):1053-1060.
20. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005;4(1):1-9.
21. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 2005;234(2):468-478. (Pubitemid 40139918)
22. Ryeom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol 2004;5(4):231-239.
23. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004;14(4):559-578. (Pubitemid 38444568)
24. Shimizu J, Dono K, Gotoh M, et al. Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci 1999;44(7):1330-1337. (Pubitemid 29404293)
25. Kim T, Murakami T, Hasuike Y, et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 1997;7(4):683-688. (Pubitemid 28365618)
26. Tsuda N, Okada M, Murakami T. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 2010;73(1):137-142.
27. Ichida F, Tsuji T, Omata M, et al. New Inuyama classification: new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996;6(2):112-119. (Pubitemid 27059904)
28. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60(8):646-649.
29. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991;22(2):233-237.
30. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992;183(1):59-64.
31. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195(3):785-792.
32. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005;237(1):89-98. (Pubitemid 41346150)
33. Ni Y, Marchal G, Lukito G, Yu J, Mühler A, Baert AL. MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings. Radiology 1994;190(3):753-758. (Pubitemid 24071042)
34. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008;18(8):1577-1586.
35. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996;199(1):177-183. (Pubitemid 26098637)
36. Motosugi U, Ichikawa T, Tominaga L, et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 2009;19(11):2623-2629.
37. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008;43(7):504-511.
38. Taouli B, Tolia AJ, Losada M, et al. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol 2007;189(4):799-806. (Pubitemid 47479760)
39. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010;254(1):47-66.
40. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11(2):102-125.
41. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echoplanar MR imaging. Radiology 1999;210(3):617-623. (Pubitemid 29124018)
42. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging - pilot study. Radiology 2008;249(3):891-899.